Drug-Resistant Fungal Threat Candida Auris Spreads Across 28 States: What Northwest Florida Patients Need to Know

Last updated: August 11, 2026

NewsWK — As federal public health officials track the ongoing spread of a potentially dangerous, drug-resistant fungal pathogen across the United States, healthcare providers and families across Northwest Florida are maintaining increased vigilance. The organism, known as Candida auris, has established a presence in more than half of U.S. states this year, primarily threatening hospitalized individuals, nursing home residents, and patients requiring intensive medical intervention.

Data compiled by the U.S. Centers for Disease Control and Prevention through its National Notifiable Diseases Surveillance System reveals that 28 states have documented clinical infections from the multidrug-resistant yeast so far this year. While the fungus presents negligible risk to healthy individuals going about their daily lives, its ability to survive on medical equipment and resist conventional antifungal treatments makes it an urgent operational challenge for acute care facilities and nursing homes.

Why it matters here

For residents in Escambia and Santa Rosa counties, understanding the nature of Candida auris is essential when navigating long-term care facilities, rehabilitation centers, and regional hospital systems. Northwest Florida serves a growing retiree population, many of whom utilize specialized care settings where the pathogen spreads most readily.

Local healthcare systems in Pensacola, Gulf Breeze, and Crestview rely on rigorous infection control, thorough environmental cleaning, and proactive patient screening to prevent localized outbreaks. Because the yeast can linger on surfaces and colonize a patient’s skin without immediate symptoms, effective sanitation protocols and accurate diagnostic screening serve as the primary line of defense. Ensuring local facilities maintain strict hygiene standards without creating unnecessary operational delays or driving up healthcare costs remains a top priority for patients and caregivers throughout the region.

National trends and regional case distribution

According to federal surveillance data updated through August 1, health authorities recorded 3,544 clinical cases of Candida auris nationwide this year. That total represents a modest decline from the 4,262 clinical cases reported during the same period in the prior year. Despite this slight reduction following a multi-year surge between 2022 and 2024, medical professionals emphasize that the fungus continues to pose a formidable challenge due to its resistance to multiple standard antifungal medications.

In addition to active clinical infections—where patients develop measurable illness—public health agencies recorded 3,325 screening detections nationwide as of August 1. Screening tests identify patients who are colonized with the yeast but show no physical symptoms. While colonized individuals do not feel sick, they can unknowingly harbor the pathogen on their skin and transfer it to shared medical devices, bedding, or healthcare staff.

Regional data shows significant variation across the country:

• Southern States: Health departments across the South reported more than 1,400 clinical cases, representing the largest regional concentration. Texas led the region with 437 clinical diagnoses, followed by Tennessee with 293 and Georgia with 193.
• California: Reported the highest single-state total in the nation, recording 887 clinical cases.
• Midwest: Illinois, Indiana, Michigan, Ohio, and Wisconsin collectively logged 751 clinical cases.
• Mountain Region: Recorded 200 clinical cases, with Arizona accounting for the vast majority at 171 diagnoses.
• Northeast: Cases remained concentrated in a small number of states, including 131 in Pennsylvania and 55 in New Jersey.

Understanding the pathogen and patient risks

First identified by medical researchers in Japan in 2009, Candida auris made its initial appearance in the United States in 2016. Between 2019 and 2021, seventeen states confirmed their first-ever cases, prompting federal health officials to categorize the yeast as an emerging, urgent health threat within medical environments.

The pathogen primarily affects individuals dealing with severe underlying medical conditions or those undergoing long-term, complex treatments. Patients who require invasive medical apparatus—such as central venous catheters, feeding tubes, or breathing tubes—face the highest statistical risk of acquiring an infection.

Symptoms of Candida auris can vary widely based on where the infection takes hold within the body. Localized skin infections may present differently than invasive bloodstream infections, though common signs include persistent fever and chills that do not respond to standard antibacterial therapy. Because these symptoms mirror many other hospital-acquired infections, specialized laboratory testing is required to confirm the presence of the fungus.

Protecting vulnerable loved ones

For families managing care for elderly or immunocompromised relatives in Northwest Florida, medical experts advise open communication with facility administrators regarding infection prevention protocols. Asking whether a facility conducts routine screening for high-risk transfers and ensuring that care teams adhere strictly to hand hygiene standards can provide added peace of mind.

While healthcare providers continue to monitor cases and refine treatment strategies, maintaining robust facility sanitation and targeted patient screening remains the most effective, fiscally responsible approach to containing the pathogen without imposing broad, heavy-handed administrative burdens on the healthcare system.